Is Xolair still in shortage in 2026? Get the latest update on Omalizumab availability, pricing, biosimilar options, and how to find it in stock near you.
If you rely on Xolair (Omalizumab) for asthma, chronic hives, nasal polyps, or food allergy, you've probably dealt with at least one frustrating moment over the past couple of years when your pharmacy couldn't fill your prescription. The Xolair supply situation has been one of the more challenging medication access stories in recent memory.
So where do things stand in 2026? Is Xolair still hard to get? What's changed? And what should you be doing right now to protect your access to treatment? This article breaks it all down.
The short answer: it depends on where you are and which dose you need.
Xolair supply has improved compared to the acute shortages seen in late 2023 and throughout 2024, but the situation isn't fully resolved. Some doses and formulations remain intermittently constrained, and availability can vary significantly by region and pharmacy.
The biggest factor driving the ongoing tightness is simple: demand still exceeds pre-2024 projections. The February 2024 FDA approval of Xolair for IgE-mediated food allergy opened the medication up to millions of new patients, and the system is still adjusting.
Additionally, the FDA-approved biosimilar Omlyclo (Omalizumab-igec) is gradually entering the market, which is helping to relieve pressure — but biosimilar adoption takes time as insurers update formularies and prescribers gain comfort with the product.
Several factors have contributed to the Xolair shortage:
An estimated 33 million Americans have food allergies, and Xolair became the first FDA-approved treatment to reduce the risk of allergic reactions from accidental exposure. This single approval expanded the eligible patient population dramatically.
Xolair is a monoclonal antibody produced from living cells in bioreactors. The manufacturing process takes months and involves extensive quality control. Scaling up production isn't as simple as running an extra batch — it requires validated facilities, regulatory approvals, and time.
Xolair requires refrigeration and is only available through specialty pharmacies or doctor's offices. This narrow distribution channel means that when supply is tight, patients have fewer places to look.
Even when Xolair is physically available, insurance barriers can create their own delays. Prior authorization requests, step therapy requirements, and specialty pharmacy mandates can add days or weeks to the process.
For a deeper dive into these factors, see Why Is Xolair So Hard to Find?
Xolair remains one of the more expensive medications on the market:
If cost is a concern, our detailed guide covers all the ways to save: How to Save Money on Xolair in 2026.
The biggest development for Xolair access is the FDA-approved biosimilar Omlyclo (Omalizumab-igec) from Mylan/Viatris. A biosimilar is essentially the biologic equivalent of a generic — it works the same way, is equally safe, and meets the same FDA standards.
As insurers add Omlyclo to their formularies and more pharmacies begin stocking it, this should meaningfully improve supply and potentially lower costs. Ask your doctor if the biosimilar is an option for you.
Xolair is available in prefilled syringes and autoinjectors that allow trained patients to self-inject at home. This reduces dependency on doctor's office supply and gives you more flexibility in sourcing the medication through different specialty pharmacies.
If Xolair remains difficult to access for your condition, alternative biologics like Dupixent, Nucala, Fasenra, or Tezspire may be appropriate depending on your diagnosis. See Alternatives to Xolair for a full comparison.
Here's what we recommend:
For a complete walkthrough, read How to Find Xolair in Stock Near You.
The Xolair shortage has been a difficult reality for patients managing serious allergic conditions. While 2026 is better than 2024 in terms of supply, we're not entirely out of the woods. The biosimilar rollout and continued manufacturing expansion are positive signs, but patients should still be proactive about sourcing their medication.
Use tools like Medfinder, communicate early with your doctor and pharmacy, explore the biosimilar option, and stay informed. Your health depends on consistent treatment, and with the right strategy, you can stay on track.
For more information about Xolair, explore our related guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
